Revisión sobre inhibidores de la enzima lactato deshidrogenasa.
Fecha
2020-10-21
Autores
Título de la revista
ISSN de la revista
Título del volumen
Editor
Jaén: Universidad de Jaén
Resumen
La lactato deshidrogenasa (LDH) es una enzima tetramérica que cataliza la reacción reversible de conversión de piruvato en lactato, con la consiguiente formación de NAD+. Se sabe que una de estas enzimas humanas (hLDHA) juega un papel importante en el metabolismo energético de las células tumorales, razón por la que su inhibición ha sido objeto de estudio durante años, dándose a conocer un buen número de compuestos de naturaleza orgánica con actividad inhibitoria de esta enzima. Otra reacción que también cataliza la hLDHA es la conversión de glioxalato en oxalato, por lo que la inhibición específica de esta enzima se ha propuesto más recientemente como una estrategia prometedora para el tratamiento de la enfermedad denominada hiperoxaluria primaria (HOP). En el presente Trabajo Fin de Grado se describen las diferentes familias de inhibidores de LDH descritas hasta la fecha, así como los procedimientos sintéticos de una selección de estos inhibidores.
Lactate dehydrogenase (LDH) is a tetrameric enzyme that catalyzes the reversible reaction of conversion of pyruvate into lactate, with the consequent formation of NAD+. One of these human enzymes (hLDHA) is known to play an important role in the energy metabolism of tumor cells, which is why its inhibition has been studied for years, leading to a good number of organic compounds with inhibitory activity of this enzyme. Another reaction that also catalyzes hLDHA is the conversion of glyoxalate into oxalate, so specific inhibition of this enzyme has been proposed more recently as a promising strategy for the treatment of the disease called primary hyperoxaluria (PH). The present TFG covers the families of LDH inhibitors reported to date, as well as the synthetic procedures that allow a selection of these inhibitors to be obtained.
Lactate dehydrogenase (LDH) is a tetrameric enzyme that catalyzes the reversible reaction of conversion of pyruvate into lactate, with the consequent formation of NAD+. One of these human enzymes (hLDHA) is known to play an important role in the energy metabolism of tumor cells, which is why its inhibition has been studied for years, leading to a good number of organic compounds with inhibitory activity of this enzyme. Another reaction that also catalyzes hLDHA is the conversion of glyoxalate into oxalate, so specific inhibition of this enzyme has been proposed more recently as a promising strategy for the treatment of the disease called primary hyperoxaluria (PH). The present TFG covers the families of LDH inhibitors reported to date, as well as the synthetic procedures that allow a selection of these inhibitors to be obtained.